DrugPatentWatch Information on Approved Drugs and Drug Products
Biotech-U -- Online biotechnology courses covering the scientific, legal, regulatory, political, and commercial aspects of biotechnology.

ADVERTISE HERE 

Building Biotechnology: Starting, managing, and understanding biotechnology companies

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents
 To purchase a subscription and access the complete database, visit www.DrugPatentWatch.com

Drug Patent Expirations in July 2009
* Drugs may be covered by multiple patents or regulatory protections

TradenameApplicantGeneric NamePatent NumberPatent Expiration
LEVULANDusaaminolevulinic acid hydrochloride5,422,093Jul 28, 2009
LEVULANDusaaminolevulinic acid hydrochloride6,710,066Jul 28, 2009
OPTIMARKMallinckrodtgadoversetamide5,130,120Jul 14, 2009
OPTIMARKMallinckrodtgadoversetamide5,137,711Jul 14, 2009
OPTIMARK IN PLASTIC CONTAINERMallinckrodtgadoversetamide5,130,120Jul 14, 2009
OPTIMARK IN PLASTIC CONTAINERMallinckrodtgadoversetamide5,137,711Jul 14, 2009
PAXIL CRGlaxosmithklineparoxetine hydrochloride5,789,449Jul 6, 2009
TRITECGlaxosmithklineranitidine bismuth citrate5,008,256Jul 17, 2009

SUBSCRIPTIONS

If this newsletter has been forwarded to you and you would like to subscribe, go to http://www.DrugPatentWatch.com/newsletter

If you no longer wish to receive this newsletter, go to http://www.DrugPatentWatch.com/newsletter/unsubscribe.php

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek independent professional advice before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

All trademarks and applicant names are the property of their respective owners or licensors.